Safety of Adipose-Derived Stem Cell Stromal Vascular Fraction

NCT02590042 | Unknown Phase 1

• 1 other identifier: SJS-CT-001
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

A single-arm, open-labeled, single-center, descriptive and exploratory safety trial using ADSC-SVF-002. ADSC-SVF-002 is an autologous adipose derived stem cell (ADSC)-containing stromal vascular fraction (SVF) obtained from subcutaneous fat harvested by liposuction from a patient. As a cellular therapy product, ADSC-SVF-002 (fresh or cryopreserved) will be administered subcutaneously via injection, with or without unprocessed autologous fat (fresh or cryopreserved), into soft tissue defects and abnormally healing wounds. The primary objective of the trial is to demonstrate the safety of ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.

Conditions

Abnormally Healing Wounds; Scars; Soft Tissue Defects

Outcome Measures

Primary Outcomes (1)

• Continuous monitoring of safety via laboratory tests and physical examinations

  Continuous monitoring of safety as requested by Health Canada

  Screening, 48 hours after procedure, and at post-treatment months 1, 2 and 6

Secondary Outcomes (2)

• Physician satisfaction with wound cosmesis, assessed using the Hollander Wound Evaluation Scale

  Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6

• Patient satisfaction with wound cosmesis, assessed using the 100 mm vertical line visual analogue scale

  Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6

Study Arms (1)

ADSC-SVF-002

EXPERIMENTAL

Cells will be administered at 1x10\^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10\^6 cells/mL of defect.

Biological: ADSC-SVF-002

Interventions

ADSC-SVF-002 BIOLOGICAL

ADSC-SVF with the following identity: Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)

Also known as: ADSC-SVF manufactured by AdiSave

ADSC-SVF-002

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing.
• Subject is an adult male or non-pregnant female between the ages of 18 to 80 years.
• Subject is able to undergo a liposuction procedure in the opinion of the investigator or per facility guidelines.
• Subject is able to read, understand and sign a written Informed Consent to participate in the study.
• Subject is willing and able to comply with the study protocol, including requirements for taking and abstaining from medications.

You may not qualify if:

• The subject is a woman of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history), but is not using a highly effective method of contraception \[oral, injected or implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or male sterilization (vasectomy)\].
• Subject has a history of cancer and/or any known conditions/diseases prone to malignancy.
• Subject has significant cardiac, renal, or hepatic failure or any other disease that may interfere with the ability to interpret the results of the study.
• Subject has an infection, cellulitis, or osteomyelitis diagnosed by MRI and microbiologic culture results.
• Subject has an autoimmune disorder.
• Subject has a connective, metabolic or atrophic skin disease.
• Subject is under chronic anticoagulant therapy.
• Subject has a Body Mass Index (BMI) \>30.
• Subject is positive for HBs antigen, HCV antibody, or HIV antibody.
• Subject has received other investigational drug/drugs or unapproved medication within 3 months before registration in this study.
• Subject has a history of hematopoietic stem cell transplantation or radio immunotherapy.
• Subject has a recent and significant weight loss, the cause of which has not been determined.
• Subject has a history of hereditary linked malignancy in a first-degree relative (parent, child, sibling).
• Subject is participating in another clinical trial within 6 weeks prior to registration in this study.
• Subject has a psychiatric disorder that in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, or follow-up.

Sponsors & Collaborators

• AdiSave Inc.: lead

Study Sites (1)

Forest Hill Institute of Aesthetic Plastic Surgery

Toronto, Ontario, M6C2E3, Canada

Location

MeSH Terms

Conditions

Cicatrix

Condition Hierarchy (Ancestors)

Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Sarah HM Wong, MD

  Forest Hill Institute of Aesthetic Plastic Surgery

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Keren Leibson, PhD

CONTACT

416 785-7536; info@adisave.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 21, 2015
• First Posted: October 28, 2015
• Study Start: October 1, 2017
• Primary Completion: October 1, 2020
• Study Completion: January 1, 2021
• Last Updated: July 19, 2017

Record last verified: 2017-07

Locations

CA (1)